Amgen announced the launch of Neulasta (pegfilgrastim) Delivery Kit that allows the healthcare provider to initiate Neulasta on the same day as chemotherapy along with a full dose of Neulasta the following day.
The Neulasta Delivery Kit includes a single-use pre-filled syringe co-packaged with the new On-body Injector for Neulasta. The Neulasta Delivery Kit provides an option for patients who would not need to return to the hospital or clinic the day after chemotherapy for anything besides their Neulasta injection. On the same day as a chemotherapy session, the healthcare provider initiates Neulasta administration by using the co-packaged syringe to fill the injector and activate it. The On-body Injector is then applied to the patient, to deliver Neulasta approximately 27 hours after the administration of cytotoxic chemotherapy. Activation of the injector leads to the subsequent insertion of the subcutaneous cannula while under healthcare provider supervision. A Phase 1 pharmacokinetic study showed that the On-body Injector had a comparable profile to Neulasta delivered as the pre-filled syringe for manual use.
Neulasta is a granulocyte-colony stimulating factor approved to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with clinically significant incidence of febrile neutropenia.
For more information visit Neulasta.com.